ZOM Zomedica Corp.: institutional ownership and insider trading
Over the last 12 months insiders bought $218K and sold $0 on the open market; over its last four quarters it reported revenue of $36.9M and net income of −$19.0M.
ZOM revenue and earnings
- Quarter ended Jun 30, 2026: revenue $9.51M, net income −$3.77M
- Quarter ended Mar 31, 2026: revenue $8.80M, net income −$4.53M, EPS 0.00
- Quarter ended Dec 31, 2025: revenue $10.5M, net income −$4.53M, EPS 0.01
- Quarter ended Sep 30, 2025: revenue $8.10M, net income −$6.12M, EPS -0.01
Recent ZOM insider trades
- May 21, 2026: Klass Russell Kevin bought 104,000 shares ($10.4K)
- May 21, 2026: Klass Russell Kevin bought 216,899 shares ($23.9K)
- May 20, 2026: Powers Johnny D bought 200,000 shares ($20.0K)
- May 13, 2026: Powers Johnny D bought 300,000 shares ($33.0K)
Are insiders buying or selling ZOM?
Over the last 12 months insiders bought $218K and sold $0 of Zomedica Corp. stock on the open market (SEC Form 4).
What was ZOM's revenue last quarter?
Zomedica Corp. reported revenue of $9.51M for the quarter ended June 30, 2026, with net income of −$3.77M.